9 April 2020 – Bright Peak Therapeutics AG, a Swiss biotechnology company developing a platform to chemically synthesize and optimize the structure and function of proteins, has received a USD 35 million Series A commitment from Versant Ventures. It has been launched out of Versant’s Ridgeline Discovery Engine based in Basel, Switzerland.

Walder Wyss advised Versant Ventures in connection with this transaction. The team was led by Alexander Gutmans (Partner, Transaction/M&A & Venture Capital) and included Jessica Aeschbach Flórez (Senior Associate, Transaction/M&A) and Karina Tschon (Associate Transaction/M&A & Venture Capital).